Maman Biomedical[™]



COMPANY

Website: https://mamanbiomedical.ca/

Year Established: 2024

Patents: Provisional filed Feb 2025. Trademarks: Filed (1) Jan 2025. **Stage:** Prototyping & Validation **Industry:** Life Sciences – Fem Tech E-mail: latchmi@mamanbiomedical.ca

TEAM

Founders and Management Team:

Founder & CEO - Dr. Latchmi Raghunanan, PhD Materials Science. 5 granted patents, 15 peer-reviewed publications, 4 years leading R&D & IP at an early-stage medical device startup.

Superpowers: Strategic thinking & execution

Co-founder & CBO - Roopchand Raghunanan, PMP, PgMP. +20 years governance & executive-level leadership. Superpowers: High in EQ & Diplomacy. Fluent in Risk, Compliance & Legal.

Board of Advisors:

Medical Director & Reproductive Expert, Biomaterials Translational Scientist, BioFluid Mechanics Expert, Regulatory Expert.

FINANCIAL INFO

Revenue: Pre-revenue Monthly Burn: \$18,000 **Funding to Date:** \$302,000

Capital Seeking: \$3M Pre-Seed, for a 24-mth runway, using rolling convertibles.

USE OF FUNDS

To advance from TRL3 to TRL6.

- 37% Product Development (Salaries, lab, equipment, consumables, trials).
- 14% Business Development (Conferences, stakeholder engagement).
- 39% Operations (Office rent, non-R&D salary, insurance, IT, travel).
- 10% Legal (IP, accounting, tax).

COMPANY OVERVIEW

Problem: Over 10% of the world's population use self-administered injections for the treatment of chronic ailments. What if this were an unnecessary burden? What if you could take your medication, effectively, without the injections?

Value Proposition Statement: We eliminate the pain and inconvenience of repeated injections with our innovative drug delivery patches, ensuring consistent dosage and minimal impact on lifestyle.

Platform: We're starting with the fertility industry, because that's our why. Infertility affects every 1 in 5 couples in North America, and in vitro fertilization (IVF) – the current IVF standard of care – requires upwards of 20 injections over 14 days per cycle.

Technology: Our proprietary microneedle drug delivery technologies include:

- Maman Patch™, our dissolving microarray patch that provides consistent hormone delivery without injections; and
- Maman Port ™, our non-dissolving alternative that facilitates the pain-free delivery of injectable medications.

Current State of Development: Prototyping & Validation

MARKET

Target Market: Global IVF Drug Market, valued at \$25B with a 6% CAGR (2024). North American Market Opportunity: Maman Patch™: \$1B

BUSINESS MODEL AND TRACTION

Revenue Model: Maman Patch™; B2B2C - Sales via Pharmacies, premium-priced. Maman Port TM ; B2C - Over the counter consumable, value-priced.

Go to Market Strategy: Partnerships with fertility clinics and doctors established during product development.

Distribution Model/Channel Partners: Licencing agreements with major pharmaceutical manufacturers who will use their established distribution channels to Fertility Clinics and Pharmaceutical suppliers.

Current Traction:

- *Product*: Provisional patent and trademark application filed; lab space secured.
- News and Media: Featured in The Globe & Mail, CBC Toronto. Winner at Lions Lair 2024. Odlum Brown Forum Semi-Finalist. Spring Impact Top 5.
- Partnerships: Ongoing discussions with 1 potential strategic (Merck), LOIs from 3 fertility clinics; partnerships with Kindeva Drug Delivery for manufacturing, and St. Joes Hospital for clinical trial development.
- Funding: Oversubscribed Family & Friends (F&F) round closed.

MILESTONE PLAN

- 6 months: Get patch to TRL4 Phase 2 R&D drug integration and validation.
- 12 months: File patent applications; Port pilot testing and validation.
- 24 months: Patch TRL6 patch preclinical validation; Port 510k submitted.

Activities and Resources: Research & Product Development; Market Research; Business Development, Preclinical and Clinical studies. Resources: 1 Materials Scientist (CEO expertise); 1 Mitacs postdoc (Biology); 2 interns (Chemistry, Clinical); lab operations; pilot trial & Key Opinion Leader fee; operations and legal services.

Ask: We're raising a \$3M Pre-Seed round; we're on the lookout for a lead investor, deep pockets, and follow-on investors.

PARTNERS



























Maman Biomedical[™]





MAMAN Port **

